Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 201–300 of 1,000
7 tesla magnetic resonance imaging: A closer look at substantia nigra anatomy in Parkinson's disease
Lehéricy, S., Bardinet, É., Poupon, C., Vidailhet, M., & François, C. (2014) · Movement Disorders · doi:10.1002/mds.26043 · Cited by 158
“Dopaminergic neuronal loss also spreads to the neighboring groups A10 (ventral tegmental area) and A8 (retrorubral formation),(27) where it has been estimated to be as much as 50%.(28) A 30-35% increase of iron (total and ferric iron) content in the SNc of patients with PD has been reported.”
BackgroundBranchi, I., D’Andrea, I., Armida, M., Cassano, T., Pèzzola, A., Potenza, R. L., Morgese, M. G., Popoli, P., & Alleva, E. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21642 · Cited by 152
“These symptoms are associated with degeneration of the dopaminergic nigrostriatal pathway (Hirsch et al., 1988; Olanow and Tatton, 1999; Lotharius and Brundin, 2002).”
BackgroundRetinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency
Jacobs, F. M. J., Smits, S. M., Noorlander, C. W., von Oerthel, L., van der Linden, A. J. A., Burbach, J. P. H., & Smidt, M. P. (2007) · Development · doi:10.1242/dev.02865 · Cited by 140
“Interestingly, adjacent DA neurons located in the ventral tegmental area (VTA) are largely spared (Hirsch et al., 1988).”
BackgroundGold Nanostructures on Flexible Substrates as Electrochemical Dopamine Sensors
Hsu, M., Chen, Y.-L., Lee, C. Y., et al. (2012) · ACS Applied Materials & Interfaces · doi:10.1021/am301452b · Cited by 139
Temlett, J. A., Landsberg, J. P., Watt, F., & Orime, G. W. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010134.x · Cited by 137
Activity-dependent neurotransmitter respecification
Spitzer, N. C. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3154 · Cited by 136
“The loss of dopaminergic neurons in Parkinson's diseas”
BackgroundMurray, A. M., Weihmueller, F. B., Marshall, J. F., Hurtig, H. I., Gottleib, G. L., & Joyce, J. N. (1995) · Annals of Neurology · doi:10.1002/ana.410370306 · Cited by 136
Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease
McRitchie, D. A., Cartwright, H., & Halliday, G. M. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6418 · Cited by 149
Shima, T., Sarna, T., Swartz, H. M., Stroppolo, A., Gerbasi, R., & Zecca, L. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00623-5 · Cited by 135
The role of transition metals in the pathogenesis of Parkinson's disease
Kienzl, E., Puchinger, L., Jellinger, K. A., Linert, W., Stachelberger, H., & Jameson, R. F. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00210-s · Cited by 145
Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration
Zhang, S., Wang, R., & Wang, G. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00454 · Cited by 141
Distinct nigrostriatal projection systems innervate striosomes and matrix in the primate striatum
Langer, L. F., & Graybiel, A. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91114-1 · Cited by 136
Self-citationZucca, F. A., Bellei, C., Giannelli, S. G., Terreni, M., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., & Zecca, L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0453-2 · Cited by 138
“The population of pigmented neurons in the SN is the main target of the neurodegenerative process in Parkinson’s disease (PD) (Hirsch et al., 1988; Dauer at al., 2003).”
BackgroundGrosch, J., Winkler, J., & Kohl, Z. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00293 · Cited by 132
“The involvement of the nigrostriatal dopaminergic system in PD was noted as early as neuropathological studies detected the loss of melanin-containing dopaminergic neurons in the SN of affected patients (Pakkenberg and Brody, 1965; Hirsch et al., 1988).”
BackgroundMolecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases
Kampmann, M. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00806-0 · Cited by 173
“Dopaminergic neurons in the substantia nigra, pars compacta (SNc) of the midbrain are selectively vulnerable in PD 37 , whereas dopaminergic neurons in the adjacent ventral tegmental area are affected to a lesser degree 38,39 .”
Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry
Ferré, S., Diamond, I., Goldberg, S. R., Yao, L., Hourani, S. M. O., Huang, Z., Urade, Y., & Kitchen, I. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.04.002 · Cited by 150
Parkinson's disease: convergence on synaptic homeostasis
Soukup, S., Vanhauwaert, R., & Verstreken, P. (2018) · The EMBO Journal · doi:10.15252/embj.201898960 · Cited by 130
“The axon arborizations of SNc DA neurons can reach a total length of four and a half meters and give rise to more than two million synaptic contacts, all connected to one cell body (Bolam & Pissadaki, 2012).”
BackgroundInfluentialMean-field modeling of the basal ganglia-thalamocortical system. II
van Albada, S. J., Gray, R. T., Drysdale, P. M., & Robinson, P. A. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.12.013 · Cited by 140
“The pathological hallmark of PD is the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) and to a lesser extent the ventral tegmental area (VTA) (Bernheimer et al., 1973; Ehringer and Hornykiewicz, 1960; Hirsch et al., 1988; Uhl et al., 1985).”
BackgroundIn vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
“This distinction is important, since pigmented and non-pigmented neurons may display differential susceptibility to neurodegeneration in Parkinson’s disease, as has been demonstrated by several authors (Hirsch et al., 1988; Zucca et al., 2014).”
BackgroundResultGastrodin Protects Apoptotic Dopaminergic Neurons in a Toxin-Induced Parkinson’s Disease Model
Kumar, H., Kim, I., More, S. V., Kim, B.-W., Bahk, Y.-Y., & Choi, D. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/514095 · Cited by 137
“Parkinson’s disease (PD) is neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the pars compacta of the substantia nigra (SNpC), which leads to clinical symptoms of rigidity, resting tremor, and bradykinesia [1, 2].”
Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys
Ovadia, A., Zhang, Z., & Gash, D. M. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02012-8 · Cited by 143
“In both idiopathic Parkinson's disease (20) and MPTP-treated monkeys (19), neuromelanin-containing dopamine neurons are the most susceptible to degeneration.”
Unbiased Estimation of Neuronal Numbers in the Human Nucleus Coeruleus during Aging
Ohm, T. G., Busch, C., & Bohl, J. R. E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00034-1 · Cited by 133
The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems
Zaręba, M., Bober, A., Korytowski, W., Zecca, L., & Sarna, T. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00058-c · Cited by 140
Bourdenx, M., Dovero, S., Engeln, M., Bido, S., Bastide, M. F., Dutheil, N., Vollenweider, I., Baud, L., Piron, C., Grouthier, V., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0222-2 · Cited by 125
“more susceptible than non-melanized neurons both in PD patients [40] and MPTP-treated primates [41].”
BackgroundHayley, S., Crocker, S. J., Smith, P. D., Shree, T., Jackson-Lewis, V., Przedborski, S., Mount, M., Slack, R., Anisman, H., & Park, D. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-03.2004 · Cited by 125
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons of the substantia nigra pars compacta (SNc) resulting in reduced striatal dopamine (DA) and the cardinal clinical features of PD (Hirsch et al., 1988).”
BackgroundEarly Life Stress, Depression And Parkinson’s Disease: A New Approach
Dallé, E., & Mabandla, M. V. (2018) · Molecular Brain · doi:10.1186/s13041-018-0356-9 · Cited by 143
“In the basal ganglia, the substantia nigra pars compacta contains the dopaminergic neurons which degenerate in the course of PD [100].”
BackgroundAcupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model
Kang, J. M., Park, H., Choi, Y. G., Choe, I., Park, J. H., Kim, Y. S., & Lim, S. (2006) · Brain Research · doi:10.1016/j.brainres.2006.10.089 · Cited by 125
Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?
Double, K. L., Reyes, S., Werry, E. L., & Halliday, G. M. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.001 · Cited by 137
Developmental origin and fate of meso-diencephalic dopamine neurons
Smits, S. M., Burbach, J. P. H., & Smidt, M. P. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.12.003 · Cited by 134
Cunha, C. D., Gevaerd, M. S., Vital, M. A., Miyoshi, E., Andreatini, R., Silveira, R. D. R., Rn, T., & Canteras, N. S. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00211-x · Cited by 132
Tissue transglutaminase catalyzes the formation of alpha‐synuclein crosslinks in Parkinson's disease
Andringa, G., Lam, K. Y., Chegary, M., Wang, X., Chase, T. N., & Bennett, M. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-0829fje · Cited by 123
“We now confirm that α-synuclein is a substrate of tTG in the human SNpc and that the crosslinking of this protein is greatly increased in PD brain.”
BackgroundInfluentialTotal and paramagnetic metals in human substantia nigra and its neuromelanin
Zecca, L., & Swartz, H. M. (1993) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257675 · Cited by 133
Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?
Hirsch, E. C. (1992) · Annals of Neurology · doi:10.1002/ana.410320715 · Cited by 123
Simantov, R., BLINDER, E., Ratovitski, T., TAUBER, M., GABBAY, M., & Porat, S. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00102-9 · Cited by 126
Rial, D., Castro, A. A., Machado, N., Garção, P., Gonçalves, F. Q., Silva, H. B., Tomé, Â. R., Köfalvi, A., Corti, O., Raisman-Vozari, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114216 · Cited by 122
“PD is primarily characterized by a progressive loss of neuromelanin-containing dopaminergic neurons in the substantia nigra pars compacta (SNc) associated with the appearance of eosinophillic, intracytoplasmic, proteinaceous inclusions termed as Lewy bodies and dystrophic Lewy neurites in surviving neurons [2].”
BackgroundSalthun-Lassalle, B., Hirsch, E. C., Wolfart, J., Ruberg, M., & Michel, P. P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5668-03.2004 · Cited by 122
“…generally lower than in those that survive (Neuhoff et al., 2002); and (4) the expression of tyrosine hydroxylase (TH), which is augmented by increased electrical activity (Nagamoto-Combs et al., 1997), is downregulated in sick but still viable DA neurons in Parkinson disease (Hirsch et al., 1988).”
BackgroundRegional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo
Laere, K. V., Casteels, C., Lunskens, S., Goffin, K. E., Grachev, I. D., Bormans, G. M., & Vandenberghe, W. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.009 · Cited by 123
“The tracer precursor for MK-9470 was kindly donated by Merck Inc.”
BackgroundLavenex, P., Steele, M. A., & Jacobs, L. F. (2000) · The Journal of Comparative Neurology · doi:10.1002/1096-9861(20000911)425:1<97::aid-cne9>3.0.co;2-n · Cited by 69
Urrutia, P. J., Bórquez, D. A., & Núñez, M. T. (2021) · Antioxidants · doi:10.3390/antiox10010061 · Cited by 138
Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression
Maingay, M., Romero‐Ramos, M., Carta, M., & Kirik, D. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.007 · Cited by 132
“Degeneration of the DA neurons in the substantia nigra (SN) is the most prominent, whereas, in the ventral tegmental area (VTA), DA neurons are less affected (Uhl et al., 1985; Hirsch et al., 1988; Kish et al., 1988; Damier et al., 1999; Braak et al., 2004).”
BackgroundDopamine-induced programmed cell death in mouse thymocytes
Offen, D., Ziv, I., Gorodin, S., Barzilai, A., Malik, Z., & Melamed, E. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(95)00075-4 · Cited by 125
Schwarz, S. T., Xing, Y., Tomar, P., Bajaj, N. P. S., & Auer, D. P. (2016) · Radiology · doi:10.1148/radiol.2016160662 · Cited by 136
“The largest overall hyperintense volume at the fixed threshold (mean + 3 SDs of background signal intensity) was observed in the control group that underwent MT acquisition with the GE Healthcare imaging unit (233 mm3 6 73), followed by the group that underwent MT imaging with the Philips imaging unit (129 mm3 6 46);…”
MethodAging of the nigrostriatal system in the squirrel monkey
McCormack, A. L., Di Monte, D. A., Delfani, K., Irwin, I., DeLanney, L. E., Langston, W. J., & Janson, A. M. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20036 · Cited by 119
“…implicated in the greater loss of pigmented dopaminergic neurons in the substantia nigra of patients with Parkinson’s disease (Mann and Yates, 1983; Hirsch et al., 1988; Kastner et al., 1992), our monkey model represents a valuable tool for future evaluation of the mechanisms and consequences of…”
MethodLeveugle, B., Faucheux, B. A., Bouras, C., Nillesse, N., Spik, G., Hirsch, É. C., Agid, Y., & Hof, P. R. (1996) · Acta Neuropathologica · doi:10.1007/s004010050468 · Cited by 125
“The distribution of neuronal vulnerability patterns have been well described in the mesencephalon of PD patients [1, 28 , 37], and is comparable to some degree to the severe loss of LF-immunoreactive nigral neurons reported in the present study.”
ResultSelf-citationKastenhuber, E., Kratochwil, C. F., Ryu, S., Schweitzer, J., & Driever, W. (2010) · Journal of Comparative Neurology · doi:10.1002/cne.22214 · Cited by 119
Reproducible generation of human midbrain organoids for in vitro modeling of Parkinson’s disease
Nickels, S., Modamio, J., Mendes-Pinheiro, B., Monzel, A. S., Betsou, F., & Schwamborn, J. C. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.101870 · Cited by 137
Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins
Double, K. L., Zecca, L., Costi, P., Mauer, M., Griesinger, C., Ito, S., Ben‐Shachar, D., Bringmann, G., Fariello, R. G., Riederer, P., et al. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752583.x · Cited by 119
“NM-containing cells of the SN are reported to be more vulnerable to neurodegeneration in PD (Hirsch et al., 1988), and patients suffering a drug-induced parkinsonian syndrome during life exhibited changes in NM consistent with an active disease process (Langston et al.”
BackgroundIdentification of neurodegenerative factors using translatome–regulatory network analysis
Brichta, L., Shin, W., Jackson-Lewis, V., Blesa, J., Yap, E.-L., Walker, Z., Zhang, J., Roussarie, J.-P., Alvarez, M. J., Califano, A., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4070 · Cited by 118
Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian
Barcia, C., Bautista‐Hernández, V., Sánchez-Bahíllo, A., Fernández‐Villalba, E., Faucheux, B. A., Poza, M., Barreiro, A. F., Hirsch, É. C., & Herrero, M. T. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0256-2 · Cited by 121
“Parkinson’s disease (PD) is characterised by a differential vulnerability of dopaminergic neurons in the mesencephalon, with the highest degree of neuronal loss in the substantia nigra pars compacta (SNpc) (Hirsch et al., 1988).”
BackgroundVarastet, M., RICHE, D., Mazière, M., & Hantraye, P. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90006-x · Cited by 141
Modifications of the iron–neuromelanin system in Parkinson's disease
Fasano, M., Bergamasco, B., & Lopiano, L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03638.x · Cited by 117
“Histological evidence shows that the more pigmented neurones are the first ones to degenerate, suggesting that NM depletion does not occur at random (Hirsch et al. 1988).”
BackgroundLiang, C., Nelson, O., Yazdani, U., Pasbakhsh, P., & German, D. C. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20098 · Cited by 117
“Furthermore, NM pigment has been shown to bind neurotoxins such as 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP; D’Amato et al., 1987) and paraquat (Lindquist et al., 1988), which could serve as a “toxin pool” within the catecholaminergic neurons.”
BackgroundAssociation study between iron-related genes polymorphisms and Parkinson's disease
Borie, C., Gasparini, F., Verpillat, P., Bonnet, A.-M., Agid, Y., Hetet, G., Brice, A., Dürr, A., & Grandchamp, B. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0704-6 · Cited by 143
“In addition, the vulnerable neurons in PD are particularly sensitive to oxidative stress that may be induced by iron [ 11 ].”
BackgroundSelf-citationHo, A., & Blum, M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-15-05614.1998 · Cited by 117
Faucheux, B. A., Martin, M., Beaumont, C., Hunot, S., Hauw, J., Agid, Y., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01118.x · Cited by 116
“The boundaries of subregions were delineated according to Hirsch et al. (1988).”
BackgroundSelf-citationEnochs, W. S., Sarna, T., Zecca, L., Riley, P. A., & Swartz, H. M. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260963 · Cited by 123
“stantia nigra during normal aging and in PD, which are consistent with observations that the most highly pigmented neurons in this brain region are most susceptible to death (Pakkenberg and Brody, 1965; Graham, 1979; Mann and Yates, 1979, 1983; Hirsch et al., 1988 ) and evidence that this may be due to oxidative stres…”
BackgroundResultMidbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease
Halliday, G. M., McRitchie, D. A., Cartwright, H., Pamphlett, R., Hely, M. A., & Morris, J. G. (1996) · Journal of Clinical Neuroscience · doi:10.1016/s0967-5868(96)90083-1 · Cited by 128
Association between waking EEG slowing and REM sleep behavior disorder in PD without dementia
Gagnon, J.-F., Fantini, M. L., Bédard, M.-A., Petit, D., Carrier, J., Rompré, S., Décary, A., Panisset, M., & Montplaisir, J. (2004) · Neurology · doi:10.1212/01.wnl.0000106460.34682.e9 · Cited by 114
Sayre, L. M. (1989) · Toxicology Letters · doi:10.1016/0378-4274(89)90168-9 · Cited by 117
Blunt, S. B., Jenner, P., & Marsden, C. D. (1993) · Movement Disorders · doi:10.1002/mds.870080202 · Cited by 115
Ni, A., & Ernst, C. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.826193 · Cited by 132
The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease
Vazey, E. M., & Aston-Jones, G. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2012.00048 · Cited by 114
“In PD the SN-DA neurons are affected whereas the predominant DAergic input to PFC arises from the ventral tegmental area, a population relatively spared in this disease (Hirsch et al., 1988; Braak et al., 2004; Maingay et al., 2006).”
BackgroundParain, K., Hapdey, C., Rousselet, E., Marchand, V., Dumery, B., & Hirsch, É. C. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03195-0 · Cited by 115
Nicotinic receptors as CNS targets for Parkinson's disease
Quik, M., Bordia, T., & O’Leary, K. T. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.015 · Cited by 123
“Studies to understand the molecular basis for this enhanced vulnerability have linked calbindin to nigrostriatal dopamine neuron survival [116– 118] while neuromelanin has been negatively associated [119–122].”
BackgroundJoyce, J. N., Smutzer, G., Whitty, C. J., Myers, A., & Bannon, M. J. (1997) · Movement Disorders · doi:10.1002/mds.870120609 · Cited by 113
Postmortem studies in Parkinson's disease
Hartmann, A. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.3/ahartmann · Cited by 130
“Moreover, within each cell group, nonpigmented neurons are spared relative to the total population of TH-positive neurons and relative to the population of pigmented neurons.(4) There is also a regional selective vulnerability of DA neurons within the SNpc to cell death in PD.”
BackgroundLinert, W., Bridge, M. H., Huber, M., Bjugstad, K. B., Grossman, S. H., & Arendash, G. W. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00029-0 · Cited by 123
Rodríguez, M., Barroso‐Chinea, P., Abdala, P., Obeso, J. A., & González‐Hernández, T. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7624 · Cited by 122
Gerlach, M., Double, K. L., Ben‐Shachar, D., Zecca, L., Youdim, M. B. H., & Riederer, P. F. (2003) · Neurotoxicity Research · doi:10.1007/bf03033371 · Cited by 116
En1 and Wnt signaling in midbrain dopaminergic neuronal development
Alves dos Santos, M. T., & Smidt, M. P. (2011) · Neural Development · doi:10.1186/1749-8104-6-23 · Cited by 111
Evolutionary and biomedical consequences of internal melanins
Dubey, S., & Roulin, A. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12231 · Cited by 120
“The concentration of neuromelanin decreases as pigmented neurons are selectively lost, whereas nonpigmented neurons are generally spared during the progression of the disease (Fedorow et al., 2005; He et al., 2011; Hirsch et al., 1988; Slominski et al., 2004).”
BackgroundModulation of α-Synuclein Aggregation by Dopamine: A Review
Leong, S. L., Cappai, R., Barnham, K. J., & Pham, C. L. L. (2009) · Neurochemical Research · doi:10.1007/s11064-009-9986-8 · Cited by 119
“In PD, it is the neuromelanin containing dopaminergic neurons that are selectivity lost [26, 27 ].”
BackgroundParkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons
Ren, Y., Jiang, H., Hu, Z., Fan, K., Wang, J., Janoschka, S., Wang, X., Ge, S., & Feng, J. (2015) · Stem Cells · doi:10.1002/stem.1854 · Cited by 109
Bohic, S., Murphy, K., Paulus, W., Cloetens, P., Salomé, M., Susini, J., & Double, K. (2008) · Analytical Chemistry · doi:10.1021/ac801817k · Cited by 109
Potential sources of increased iron in the substantia nigra of parkinsonian patients
Gerlach, M., Double, K. L., Youdim, M. B. H., & Riederer, P. F. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_21 · Cited by 122
“A relationship between the loss of the dopaminergic SN cells and their NM content has been reported (Hirsch et al., 1988), suggesting a role of NM for neurodegeneration in PD.”
BackgroundHerrero, M. T., Hirsch, É. C., Kästner, A., Ruberg, M., Luquín, M. R., Laguna, J., Javoy-Agid, F., Obeso, J. A., & Agid, Y. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90349-k · Cited by 119
Self-citationShin, E., Dang, D., Tran, T.-V., Tran, H., Jeong, J. H., Nah, S.-Y., Jang, C., Yamada, K., Nabeshima, T., & Kim, H. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0897-y · Cited by 110
“In addition, it is certain that dopaminergic cell bodies in the substantia nigra are progressively degenerated in PD patients (Hirsch et al. 1988; Pakkenberg et al. 1991), but there is a lack of histological evidence for nigral dopaminergic loss following chronic MA abuse.”
BackgroundHung, H.-C., & Lee, E. H. Y. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(96)00062-9 · Cited by 116
Goemaere, J., & Knoops, B. (2011) · The Journal of Comparative Neurology · doi:10.1002/cne.22689 · Cited by 112
“With regard to Prdxs, the staining pattern was identical in the SNC and in the VTA (Supporting Fig.”
BackgroundHantraye, P., Varastet, M., Peschanski, M., RICHE, D., Césaro, P., Jc, W., & Mazière, M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90295-q · Cited by 124
Hynes, M., Poulsen, K., Armanini, M. P., Berkemeier, L. R., PHILLIPS, H. S., & Rosenthal, A. (1994) · Journal of Neuroscience Research · doi:10.1002/jnr.490370118 · Cited by 119
“Degeneration of dopaminergic neurons in the pars compacta region of the substantia nigra is a primary neurochemical feature of the disease (Hirsch et al., 1988), and striatal dopamine concentrations are decreased by 80-99% in these patients (Hornykiewicz, 1988).”
BackgroundCaspase‐3 activation in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated mice
Turmel, H., Hartmann, A., Parain, K., Douhou, A., Srinivasan, A. N., Agid, Y., & Hirsch, É. C. (2001) · Movement Disorders · doi:10.1002/mds.1037 · Cited by 111
Self-citationCunha, C. D., Angelucci, M. E. M., Canteras, N. S., Wonnacott, S., & Takahashi, R. N. (2002) · Cellular and Molecular Neurobiology · doi:10.1023/a:1020736131907 · Cited by 125
“compacta (SNc) that project predominantly to the striatum (Hirsch et al., 1988).”
BackgroundPathological dynamics of activated microglia following medial forebrain bundle transection
Cho, B. P., Song, D. Y., Sugama, S., Shin, D. H., Shimizu, Y., Kim, S. S., Kim, Y. S., & Joh, T. H. (2006) · Glia · doi:10.1002/glia.20265 · Cited by 106
“The population of activated microglia sticking to the degenerating DA axons moved caudally along the axons toward the ventral tegmental area (VTA), which is located just caudal to the caudal portion of the nigrostriatal DA fibers (Fig.”
BackgroundInfluentialObata, T., & Chiueh, C. C. (1992) · Journal of Neural Transmission · doi:10.1007/bf01245361 · Cited by 110
Ubiquitin and Receptor-Dependent Mitophagy Pathways and Their Implication in Neurodegeneration
Fritsch, L. E., Moore, M. E., Sarraf, S. A., & Pickrell, A. M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.10.015 · Cited by 110
“PD is characterized by the preferential degeneration of dopaminergic (DA) neurons of the substantia nigra [10, 11].”
BackgroundProteomics in human Parkinson's disease research
Licker, V., Kövari, E., Hochstrasser, D. F., & Burkhard, P. R. (2009) · Journal of Proteomics · doi:10.1016/j.jprot.2009.07.007 · Cited by 110
Spatial, Temporal and Numeric Analysis of Alzheimer Changes in the Nucleus Coeruleus
Busch, C., Bohl, J. R. E., & Ohm, T. G. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00035-3 · Cited by 105
Sengstock, G. J., Olanow, C. W., Menzies, R. A., Dunn, A. J., & Arendash, G. W. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490350109 · Cited by 105
Stem cells in the treatment of Parkinson’s disease
Arenas, E. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00772-9 · Cited by 105
Liss, B., & Striessnig, J. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021214 · Cited by 118
García‐Pardo, J., Novio, F., Nador, F., Cavaliere, I., Suárez–García, S., Lope‐Piedrafita, S., Candiota, A. P., Romero‐Giménez, J., Rodríguez-Galván, B., Bové, J., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c00453 · Cited by 107
Datla, K. P., Blunt, S. B., & Dexter, D. T. (2001) · Movement Disorders · doi:10.1002/mds.1091 · Cited by 103
Influence of neuromelanin on oxidative pathways within the human substantia nigra
Double, K. L., Ben-Shachar, D., Youdim, M. B. H., Zecca, L., Riederer, P., & Gerlach, M. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00218-0 · Cited by 102
Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons
Steinkellner, T., Zell, V., Farino, Z. J., Sonders, M. S., Villeneuve, M., Freyberg, R. J., Przedborski, S., Lu, W., Freyberg, Z., & Hnasko, T. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95795 · Cited by 102
Pathophysiology of Parkinson's disease
Bonnet, A. M., & Houéto, J. (1999) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(99)80076-6 · Cited by 114
Prigent, A., Agid, Y., & Hirsch, É. C. (1994) · Brain Research · doi:10.1016/0006-8993(94)90511-8 · Cited by 107
Self-citationDepboylu, C., Stricker, S., Ghobril, J.-P., Oertel, W. H., Priller, J., & Höglinger, G. U. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.020 · Cited by 112
Burke, R. E. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.02.002 · Cited by 113
Lan, J., & Jiang, D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291883 · Cited by 105
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.